Barclays’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-125,996
| Closed | -$1.26M | – | 5607 |
|
|
2025
Q2 | $1.26M | Sell |
125,996
-2,981
| -2% | -$24K | ﹤0.01% | 3178 |
|
|
2025
Q1 | $770K | Sell |
128,977
-3,917
| -3% | -$28.8K | ﹤0.01% | 3266 |
|
|
2024
Q4 | $1.02M | Buy |
132,894
+19,683
| +17% | +$169K | ﹤0.01% | 3369 |
|
|
2024
Q3 | $1.16M | Sell |
113,211
-9,064
| -7% | -$138K | ﹤0.01% | 3265 |
|
|
2024
Q2 | $1.81M | Sell |
122,275
-224,144
| -65% | -$3.21M | ﹤0.01% | 2220 |
|
|
2024
Q1 | $4.73M | Buy |
346,419
+33,839
| +11% | +$369K | ﹤0.01% | 1894 |
|
|
2023
Q4 | $3.42M | Sell |
312,580
-9,742
| -3% | -$96.6K | ﹤0.01% | 2443 |
|
|
2023
Q3 | $3.53M | Buy |
322,322
+7,442
| +2% | +$95.2K | ﹤0.01% | 1536 |
|
|
2023
Q2 | $4.17M | Buy |
314,880
+57,924
| +23% | +$826K | ﹤0.01% | 1454 |
|
|
2023
Q1 | $3.5M | Buy |
256,956
+1,995
| +0.8% | +$35.7K | ﹤0.01% | 1787 |
|
|
2022
Q4 | $4.98M | Buy |
254,961
+33,118
| +15% | +$647K | ﹤0.01% | 1637 |
|
|
2022
Q3 | $4.23M | Buy |
221,843
+192,220
| +649% | +$4.43M | ﹤0.01% | 1269 |
|
|
2022
Q2 | $610K | Sell |
29,623
-54,376
| -65% | -$1.29M | ﹤0.01% | 2727 |
|
|
2022
Q1 | $2.7M | Buy |
+83,999
| New | +$3.05M | ﹤0.01% | 1641 |
|
Other funds holding ITOS
Barclays's ITOS Position: Q3 2025 in Review
Barclays sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 125,996 shares — an estimated $1.26M sold.
Barclays first reported a position in ITOS in Q1 2022 and held it in 14 quarters. The position peaked at $4.98M in Q4 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Barclays reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Barclays sold 125,996 iTeos Therapeutics shares in Q3 2025, an estimated $1.26M.
- Barclays first reported a position in iTeos Therapeutics in Q1 2022 and held it in 14 quarters.
- Barclays's iTeos Therapeutics position peaked at $4.98M in Q4 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.